Moreover, the combined synergistic treatment was found to increase the expression of PD‐L1 on DCs, contributing to the treatment response of ICBs and further suppressing tumor growth when combined with anti‐PD‐1 antibody. The gene discussed is CD274; the disease is neoplasm.